{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:02:22Z","timestamp":1793142142458,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea University Anam Hospital Research Support Fund","award":["R2128731"],"award-info":[{"award-number":["R2128731"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pulmonary hypertension (PH) is a complication of chronic kidney disease (CKD) that contributes to mortality. Sclerostin, a SOST gene product that reduces osteoblastic bone formation by inhibiting Wnt\/\u03b2-catenin signaling, is involved in arterial stiffness and CKD-bone mineral disease, but scanty evidence to PH. This study explored the relationship between sclerostin and PH in CKD 5, pre-dialysis end-stage kidney disease (ESKD) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional prospective observational cohort study included 44 pre-dialysis ESKD patients between May 2011 and May 2015. Circulating sclerostin levels were measured using an enzyme-linked immunosorbent assay. PH was defined as an estimated pulmonary artery systolic pressure\u2009&gt;\u200935 mmHg on echocardiography.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with higher sclerostin levels\u2009\u2265\u2009218.18pmol\/L had echocardiographic structural cardiac abnormalities, especially PH (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). On multivariate logistic analysis, sclerostin over 218.19pmol\/L was significantly associated with PH (odds ratio [OR], 41.14; 95% confidence interval [CI], 4.53-373.89, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), but multivariate Cox regression analysis showed the systemic vascular calcification score over 1 point (Hazard ratio [HR] 11.49 95% CI 2.48\u201353.14, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and PH ([HR] 5.47, 95% CI 1.30-23.06, <jats:italic>P<\/jats:italic>\u2009=\u20090.02) were risk factors for all-cause mortality in pre-dialysis ESKD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Serum sclerostin and PH have a positive correlation in predialysis ESKD patients. The higher systemic vascular calcification score and PH have an association to increase all-cause mortality in pre-dialysis ESKD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-024-02871-8","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:02:17Z","timestamp":1707548537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Higher sclerostin is associated with pulmonary hypertension in pre-dialysis end-stage kidney disease patients: a cross-sectional prospective observational cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jonghyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hyuk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jin","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Bin","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Won","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Yong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Kyung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"issue":"6","key":"2871_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1681\/ASN.2019020117","volume":"30","author":"L Zanoli","year":"2019","unstructured":"Zanoli L, Lentini P, Briet M, Castellino P, House AA, London GM, Malatino L, McCullough PA, Mikhailidis DP, Boutouyrie P. Arterial stiffness in the Heart Disease of CKD. J Am Soc Nephrol. 2019;30(6):918\u201328.","journal-title":"J Am Soc Nephrol"},{"key":"2871_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2016.02.019","volume":"30","author":"A Granata","year":"2016","unstructured":"Granata A, Clementi A, Virzi GM, Brocca A, de Cal M, Scarfia VR, Zanoli L, Ronco C, Corrao S, Malatino L. Cardiorenal syndrome type 4: from chronic kidney disease to cardiovascular impairment. Eur J Intern Med. 2016;30:1\u20136.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2871_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.krcp.2015.01.003","volume":"34","author":"SC Kim","year":"2015","unstructured":"Kim SC, Chang HJ, Kim MG, Jo SK, Cho WY, Kim HK. Relationship between pulmonary hypertension, peripheral vascular calcification, and major cardiovascular events in dialysis patients. Kidney Res Clin Pract. 2015;34(1):28\u201334.","journal-title":"Kidney Res Clin Pract"},{"issue":"3","key":"2871_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1681\/ASN.2014111111","volume":"27","author":"SD Navaneethan","year":"2016","unstructured":"Navaneethan SD, Roy J, Tao K, Brecklin CS, Chen J, Deo R, Flack JM, Ojo AO, Plappert TJ, Raj DS, et al. Prevalence, predictors, and outcomes of Pulmonary Hypertension in CKD. J Am Soc Nephrol. 2016;27(3):877\u201386.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2871_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","volume":"37","author":"SM Krishna","year":"2017","unstructured":"Krishna SM, Seto SW, Jose RJ, Li J, Morton SK, Biros E, Wang Y, Nsengiyumva V, Lindeman JH, Loots GG, et al. Wnt signaling pathway inhibitor sclerostin inhibits Angiotensin II-Induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37(3):553\u201366.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2871_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/ndt\/gfv043","volume":"30","author":"CY Yang","year":"2015","unstructured":"Yang CY, Chang ZF, Chau YP, Chen A, Yang WC, Yang AH, Lee OK. Circulating Wnt\/beta-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1356\u201363.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2871_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ndt\/gfv081","volume":"30","author":"M Morena","year":"2015","unstructured":"Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345\u201356.","journal-title":"Nephrol Dial Transplant"},{"key":"2871_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.21037\/jlpm.2018.11.05","volume":"3","author":"V Biasin","year":"2018","unstructured":"Biasin V, Obermayer-Pietsch B. Sclerostin, bone morphogenetic protein, wnt and the lung: a potential role beyond bone metabolism? J Lab Precision Med. 2018;3:102\u20132.","journal-title":"J Lab Precision Med"},{"issue":"04","key":"2871_CR9","first-page":"2","volume":"28","author":"V Biasin","year":"2019","unstructured":"Biasin V, Hoffmann J, Gschwandtner E, Klepetko W, Obermayer-Pietsch B, Kwapiszewska G. Sclerostin: moving from bone to lung. Osteologie. 2019;28(04):2.","journal-title":"Osteologie"},{"issue":"2","key":"2871_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/1479164117742316","volume":"15","author":"C Zeng","year":"2018","unstructured":"Zeng C, Guo C, Cai J, Tang C, Dong Z. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diab Vasc Dis Res. 2018;15(2):99\u2013105.","journal-title":"Diab Vasc Dis Res"},{"issue":"5","key":"2871_CR11","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/ki.2014.372","volume":"87","author":"RA de Oliveira","year":"2015","unstructured":"de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH, Britto ZM, Marques ID, Carvalho AB, Moyses RM, Jorgetti V. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2015;87(5):1039\u201345.","journal-title":"Kidney Int"},{"issue":"6","key":"2871_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/ndt\/gfy287","volume":"34","author":"N Carrillo-Lopez","year":"2019","unstructured":"Carrillo-Lopez N, Panizo S, Alonso-Montes C, Martinez-Arias L, Avello N, Sosa P, Dusso AS, Cannata-Andia JB, Naves-Diaz M. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. Nephrol Dial Transplant. 2019;34(6):934\u201341.","journal-title":"Nephrol Dial Transplant"},{"key":"2871_CR13","doi-asserted-by":"crossref","unstructured":"De Mare A, Maudsley S, Azmi A, Hendrickx JO, Opdebeeck B, Neven E, D\u2019Haese PC, Verhulst A. Sclerostin as Regulatory Molecule in Vascular Media Calcification and the bone-vascular Axis. Toxins (Basel) 2019, 11(7).","DOI":"10.3390\/toxins11070428"},{"issue":"6","key":"2871_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/gfh217","volume":"19","author":"T Adragao","year":"2004","unstructured":"Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M, Negrao AP. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1480\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2871_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"key":"2871_CR16","first-page":"87","volume":"11","author":"SA Faqih","year":"2016","unstructured":"Faqih SA, Noto-Kadou-Kaza B, Abouamrane LM, Mtiou N, El Khayat S, Zamd M, Medkouri G, Benghanem MG, Ramdani B. Pulmonary hypertension: prevalence and risk factors. Int J Cardiol Heart Vasc. 2016;11:87\u20139.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"3","key":"2871_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2871_CR18","doi-asserted-by":"crossref","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by Echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321\u201360.","DOI":"10.1093\/ehjci\/jew082"},{"key":"2871_CR19","doi-asserted-by":"crossref","unstructured":"Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):373\u20139.","DOI":"10.1002\/jbmr.217"},{"issue":"1","key":"2871_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","volume":"97","author":"A Garcia-Martin","year":"2012","unstructured":"Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA, Munoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(1):234\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2871_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248\u201355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2871_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.156","volume":"88","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, D\u2019Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015;88(2):235\u201340.","journal-title":"Kidney Int"},{"issue":"5","key":"2871_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2019.08.027","volume":"75","author":"DL Edmonston","year":"2020","unstructured":"Edmonston DL, Parikh KS, Rajagopal S, Shaw LK, Abraham D, Grabner A, Sparks MA, Wolf M. Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis. 2020;75(5):713\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2871_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/j.ajkd.2017.11.018","volume":"72","author":"M Tang","year":"2018","unstructured":"Tang M, Batty JA, Lin C, Fan X, Chan KE, Kalim S. Pulmonary hypertension, mortality, and Cardiovascular Disease in CKD and ESRD patients: a systematic review and Meta-analysis. Am J Kidney Dis. 2018;72(1):75\u201383.","journal-title":"Am J Kidney Dis"},{"key":"2871_CR25","doi-asserted-by":"crossref","unstructured":"Mare A, D\u2019Haese PC, Verhulst A. The role of Sclerostin in Bone and ectopic calcification. Int J Mol Sci 2020, 21(9).","DOI":"10.3390\/ijms21093199"},{"issue":"9","key":"2871_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molmed.2009.07.001","volume":"15","author":"V Persy","year":"2009","unstructured":"Persy V, D\u2019Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009;15(9):405\u201316.","journal-title":"Trends Mol Med"},{"issue":"12","key":"2871_CR27","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D\u2019Haese PC. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013;28(12):3024\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2871_CR28","doi-asserted-by":"publisher","first-page":"204589402096688","DOI":"10.1177\/2045894020966889","volume":"10","author":"PT Bhattacharya","year":"2020","unstructured":"Bhattacharya PT, Hameed AMA, Bhattacharya ST, Chirinos JA, Hwang WT, Birati EY, Menachem JN, Chatterjee S, Giri JS, Kawut SM, et al. Risk factors for 30-day readmission in adults hospitalized for pulmonary hypertension. Pulm Circ. 2020;10(4):2045894020966889.","journal-title":"Pulm Circ"},{"issue":"1","key":"2871_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, ESC\/ERS Scientific Document Group, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):61\u2013144.","journal-title":"Eur Respir J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-02871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-02871-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-02871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:02:34Z","timestamp":1707548554000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-02871-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-02871-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Korea University Institutional Review Board (IRB no. AN11093-001). Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All informed consent was obtained from all subjects and\/or their legal guardian(s) under Ethics approval and consent to participate section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"78"}}